Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
NuvaRing Side Effects and Science Information to be Presented to MDL Court July 28, 2009 AboutLawsuits Add Your Comments U.S. District Judge Rodney W. Sipple, who is presiding over the consolidated Multidistrict Litigation (MDL) involving women who have filed a NuvaRing lawsuit alleging that blood-clot related injuries were caused by the contraceptive ring, has scheduled a “Science Day” for December 1, 2009. During the Science Day, the court will hear presentations from the plaintiffs’ side and drug maker’s perspective to educate the court about the NuvaRing side effects alleged in the lawsuits, including what effect the combination of hormones contained in the vaginal ring has and whether it increases the risk of blood clots leading to potential deep vein thrombosis or pulmonary embolism. NuvaRing is a birth control device manufactured by Organon Pharmaceuticals, Inc., which releases etonogestrel and ethinyl estradiol through a ring that is inserted into the vagina once a month. The release of hormones is designed to prevent unwanted pregnancies, but plaintiffs allege that a side effect of NuvaRing increases the risk that women could suffer serious and potentially life-threatening injuries. Learn More About NuvaRing Lawsuits Side effects of NuvaRing may increase risk of blood clots, pumonary embolism, DVT, death. Lawsuits pending. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About NuvaRing Lawsuits Side effects of NuvaRing may increase risk of blood clots, pumonary embolism, DVT, death. Lawsuits pending. Learn More SEE IF YOU QUALIFY FOR COMPENSATION More than 100 federal NuvaRing lawsuits, all involving similar allegations that plaintiffs suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism or death after using the birth control ring, have been centralized before Judge Sipple in the U.S. District Court for the Eastern District of Missouri. The complaints charge the manufacturer with failing to fully researching their product or adequately warn about the increased risk of blood clot injuries. The NuvaRing Science Day will allow lead counsel for both plaintiffs and defendants to designate at least one attorney and experts to make a presentation of no more than two hours designed to educate the court on the background of the product and complex issues that will arise during the litigation. Judge Sipple has also indicated that the parties may record their presentations on a videotape or DVD for the Court’s future reference during the litigation. “If a Science Day presenter later becomes a witness in the litigation, the presentation may not be used to cross-examine or impeach the presenter,” wrote Judge Sipple in an order issued July 22. “The presentations are intended solely to educate the court about the specific issues in the litigation and may not be used at any other time or for any purpose, except by the Court as it deems appropriate.” The information presented will be limited to the NuvaRing, the types of injuries plaintiffs are claiming to have sustained, the correct terminology to be used in the case, and the device’s link to the formation of blood clots. The presentations are deemed confidential, will not be done under oath and will not contain information about specific Plaintiffs or cases involved in the NuvaRing litigation. Tags: Birth Control, Birth Control Ring, Blood Clot, Deep Vein Thrombosis, Heart Attack, NuvaRing, Pulmonary Embolism, Stroke Image Credit: | More NuvaRing Lawsuit Stories Sustiva Side Effects May Reduce Nuvaring Effectiveness: Study March 12, 2018 NuvaRing Warnings Issued for Women Over 35 Who Smoke August 4, 2014 NuvaRing Settlement to Move Forward for 3,800 Plaintiffs June 9, 2014 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: today) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025) Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: yesterday) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025) Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: yesterday) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)
Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: today) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025)
Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: yesterday) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025)
Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: yesterday) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)